American Journal of Obstetrics & Gynecology
Volume 192, Issue 4 , Pages 1262-1271 , April 2005

Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: Tissue microarray analysis

  • Jeffrey M. Fowler, MD

      Affiliations

    • Division of Gynecologic Oncology
    • Corresponding Author InformationReprint requests: Jeffrey M. Fowler, MD, Director, Division of Gynecologic Oncology, JG Boutselis Professor in Gynecologic Oncology, 210-M SL, 320 W 10th Ave, Columbus, OH 43210.
    • ,
  • Nilsa Ramirez, MD

      Affiliations

    • Department of Pathology
    • ,
  • David E. Cohn, MD

      Affiliations

    • Division of Gynecologic Oncology
    • ,
  • Nicole Kelbick, PhD

      Affiliations

    • Center for Biostatistics, and The Arthur James Cancer Hospital and Richard Solove Research Institute, The Ohio State University Medical School, Columbus, Ohio
    • ,
  • James Pavelka, MD

      Affiliations

    • Division of Gynecologic Oncology
    • ,
  • Inbar Ben-Shachar, MD

      Affiliations

    • Division of Gynecologic Oncology
    • ,
  • Carl Morrison, MD, DVM

      Affiliations

    • Department of Pathology

Received 31 December 2004 ,Revised 6 January 2005 ,Accepted 6 January 2005.

References 

  1. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De putte LB, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063–1073
  2. Dixon DA. Regulation of COX-2 expression in human cancers. Prog Exp Tumor Res. 2003;37:52–71
  3. Umar A, Viner JL, Anderson WF, Hawk ET. Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol. 2003;26:S48–S57
  4. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–890
  5. Harris RE. Epidemiology of breast cancer and nonsteroidal anti-inflammatory drugs. In:  Harris RE editors. COX-2 blockade in cancer prevention and therapy. Towowata, NJ: Humana Press, Inc; 2003;p. 35–56
  6. Brueggemeier RW, Richards JA, Petrel TA. Aromatase and cyclooxygenases: enzymes in breast cancer. J Steroid Biochem Mol Biol. 2003;86:501–507
  7. Richards JA, Petrel TA, Brueggemeier RW. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol. 2002;80:203–212
  8. Simon R MM, Sauter G. Tissue microarray in cancer diagnosis. Expert Rev Mol Diagn 2003;3:421-30.
  9. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol. 2002;26:312–319
  10. Oshima M, Dinchuk JE, Kargan SL, et al. Suppression of intestinal polyposis in Apc 716 knockout mice by inhibition of cycloxygenase-2. Cell. 1996;87:803–809
  11. Kyulkami S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res. 2001;7:429–434
  12. Wardlaw SA, March TH, Belinsky SA. Cyclooxygnease-2 expression is abundant in alveolar type II cells in lung cancer-senstive mouse strains and in premalignant lesions. Carcinogenesis. 2000;21:1371–1377
  13. Cao QJ, Einstein MH, Anderson PS, Runowicz CD, Balan R, Jones JG. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol. 2002;21:147–154
  14. Ferrandina G, Legge F, Ranelletti FO, Zannoni GF, Maggiano N, Evangelisti A, et al. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer. 2002;95:801–807
  15. Landen CN, Mathur SP, Richardson MS, Creasman WT. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol. 2003;188:1174–1176
  16. Hayes EC, Rock JA. COX-2 Inhibitors and their role in gynecology. Obstet Gynecol Surv. 2002;57:768–780
  17. Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K, Miyazaki K. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol. 2002;33:213–219
  18. Wulfing P, Diallo R, Muller C, Wulfing C, Poremba C, Heinecke A, et al. Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarry analysis. J Cancer Res Clin Oncol. 2003;129:375–382
  19. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy R, Fitzgerald D, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA. 1999;282:1254–1257
  20. Gehrig PA, Van Le L, Olatidoye B, Geradts J. Estrogen receptor status, determined by immunohistochemistry, as a predictor of recurrence of stage I endometrial carcinoma. Cancer. 1999;86:2083–2089
  21. Inoue M. Current molecular aspects of the carcinogenesis of the uterine endometrium. Int J Gynecol Cancer. 2001;11:339–348
  22. Risinger JI, Maxwell GL, Chandramouli GVR, Jazaeri A, Aprelikova O, Patterson T, et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Research. 2003;63:6–11
  23. Jabbour HN, Milne SA, Williams AR, Anderson RA, Boddy SC. Expression of COX-2 and PGE synthase and synthesis of PGE(2)in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer. 2001;85:1023–1031
  24. Tamura M, Sebastian S, Yang S, Gurates B, Ferrer K, Sasano H, et al. Up-regulation of cyclooxygenase-2 expression and prostaglandin synthesis in endometrial stromal cells by malignant endometrial epithelial cells. A paracrine effect mediated by prostaglandin E2 and nuclear factor-kappa B. J Biol Chem. 2002;277:26208–26216
  25. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis. 2000;21:427–433
  26. Davies G, Martin LA, Sacks N, Dowsett M. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol. 2002;13:669–678
  27. Watanabe K, Sasano H, Harada N, Ozaki M, Niikura H, Sato S, et al. Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. Am J Pathol. 1995;146:491–500
  28. Bertstein LM, Tchernobrovkina AE, Gamajunova VB, Kovalevskij AJ, Vasilyev DA, Chepik OF, et al. Tumor estrogen content and clinco-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol. 2003;129:245–249
  29. Santen RJ. To block estrogen's synthesis or action: that is the question. J Clin Endocrinol Metab. 2002;87:3007–3012
  30. Chow LW, Wong JL, Masakazu T. Celocoxib andti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol. 2003;86:443–447

 Presented at the 23rd Annual Meeting of the American Gynecological and Obstetrical Society, September 9-11, 2004, Bolton Landing, NY.

PII: S0002-9378(05)00072-4

doi: 10.1016/j.ajog.2005.01.009

American Journal of Obstetrics & Gynecology
Volume 192, Issue 4 , Pages 1262-1271 , April 2005

Article Tools

* Image Usage & Resolution